L
Lynda Coughlan
Researcher at University of Maryland, Baltimore
Publications - 62
Citations - 2535
Lynda Coughlan is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Vaccination & Virus. The author has an hindex of 23, co-authored 51 publications receiving 1487 citations. Previous affiliations of Lynda Coughlan include British Heart Foundation & University of Glasgow.
Papers
More filters
Journal ArticleDOI
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
Kris M. White,Romel Rosales,Soner Yildiz,Thomas Kehrer,Lisa Miorin,Elena Moreno,Sonia Jangra,Melissa B. Uccellini,Raveen Rathnasinghe,Lynda Coughlan,Carles Martínez-Romero,Jyoti Batra,Ajda Rojc,Mehdi Bouhaddou,Jacqueline M. Fabius,Kirsten Obernier,Marion Dejosez,Maria Jose Guillen,Alejandro Losada,Pablo Aviles,Michael Schotsaert,Thomas P. Zwaka,Marco Vignuzzi,Kevan M. Shokat,Nevan J. Krogan,Adolfo García-Sastre +25 more
TL;DR: In this article, the authors showed that plitidepsin (aplidin) possesses antiviral activity (90% inhibitory concentration = 0.88 nM) that is more potent than remdesivir against SARS-CoV-2 in vitro by a factor of 27.5.
Journal ArticleDOI
Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
Richard D Antrobus,Lynda Coughlan,Tamara Berthoud,Matthew D. J. Dicks,Adrian V. S. Hill,Teresa Lambe,Sarah C. Gilbert +6 more
TL;DR: ChAdOx1 is a promising vaccine vector that could be used to deliver vaccine antigens where strong cellular immune responses are required for protection and is demonstrated to be safe and immunogenic.
Journal ArticleDOI
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
Raffael Nachbagauer,Jodi Feser,Abdollah Naficy,David I. Bernstein,David I. Bernstein,Jeffrey T. Guptill,Emmanuel B. Walter,Emmanuel B. Walter,Franceso Berlanda-Scorza,Daniel Stadlbauer,Patrick C. Wilson,Teresa Aydillo,Mohammad Amin Behzadi,Disha Bhavsar,Carly M. Bliss,Christina Capuano,Juan Manuel Carreño,Veronika Chromikova,Carine Claeys,Lynda Coughlan,Alec W. Freyn,Chris Gast,Andres Javier,Kaijun Jiang,Chiara Mariottini,Meagan McMahon,Monica M. McNeal,Monica M. McNeal,Alicia Solórzano,Alicia Solórzano,Shirin Strohmeier,Shirin Strohmeier,Weina Sun,Marie Van der Wielen,Bruce L Innis,Adolfo García-Sastre,Peter Palese,Florian Krammer +37 more
TL;DR: The results suggest that chimeric hemagglutinins have the potential to be developed as universal vaccines that protect broadly against influenza viruses.
Journal ArticleDOI
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice
Alec W. Freyn,Jamile Ramos da Silva,Jamile Ramos da Silva,Victoria C. Rosado,Carly M. Bliss,Matthew Pine,Barbara L. Mui,Ying K. Tam,Thomas D. Madden,Luís Carlos de Souza Ferreira,Drew Weissman,Florian Krammer,Lynda Coughlan,Peter Palese,Norbert Pardi,Raffael Nachbagauer +15 more
TL;DR: The immunity conferred by nucleoside-modified mRNA-lipid nanoparticle vaccines provided protection from challenge with pandemic H1N1 virus at 500 times the median lethal dose after administration of a single immunization, and the combination vaccine protected from morbidity at a dose of 50 ng per antigen.
Journal ArticleDOI
Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection
Raveen Rathnasinghe,Shirin Strohmeier,Fatima Amanat,Virginia L. Gillespie,Florian Krammer,Adolfo García-Sastre,Lynda Coughlan,Lynda Coughlan,Michael Schotsaert,Melissa B. Uccellini +9 more
TL;DR: The K18-hACE2 model provides a stringent model for testing vaccines and antivirals, whereas the adenovirus delivery system has the flexibility to be used across multiple genetic backgrounds and modified mouse strains.